Results 21 to 30 of about 195,005 (265)
Pharmaceutics, 2023 Gold nanoparticles (AuNPs) are widely used in biomedicine due to their remarkable therapeutic applications. However, little is known about their cytotoxic effects on the ubiquitin proteasome system (UPS).
Bashiru Ibrahim +4 more
doaj +1 more source
Cell Chemical Biology, 2017 While proteasome inhibitors are now well-established research tools and chemotherapeutics, proteasome activators are much less explored. In this issue of Cell Chemical Biology, in a study from the groups of Berkers and Ovaa (Leestemaker et al., 2017), a chemical screen was used to identify a p38 MAPK inhibitor as a proteasome activator.
Krahn, Jan +2 more
openaire +3 more sources
Proteasome beta-4 subunit contributes to the development of melanoma and is regulated by miR-148b
Tumor Biology, 2017 The proteasome beta-4 subunit is required for the assembly of 20S proteasome complex, forming a pivotal component for the ubiquitin–proteasome system. Emerging evidence indicates that proteasome beta-4 subunit may be involved in underlying progression ...
Xiaodong Zhang +7 more
doaj +1 more source
Pharmaceutics, 2023 Chordomas account for approximately 1–4% of all malignant bone tumors and 20% of primary tumors of the spinal column. It is a rare disease, with an incidence estimated to be approximately 1 per 1,000,000 people.
Amrendra K. Ajay +14 more
doaj +1 more source
Role of S5b/PSMD5 in Proteasome Inhibition Caused by TNF-α/NFκB in Higher Eukaryotes
Cell Reports, 2012 The ubiquitin-proteasome system is essential for maintaining protein homeostasis. However, proteasome dysregulation in chronic diseases is poorly understood.
Sang Mi Shim +5 more
doaj +1 more source
Cells, 2023 Hepatitis C virus (HCV) is constantly exposed to considerable oxidative stress, characterized by elevated levels of reactive oxygen species, including hydrogen peroxide (H2O2), during acute and chronic infection in the hepatocytes of patients.
Hyunyoung Yoon, Kyung Lib Jang
doaj +1 more source
Biochemical Pharmacology, 2015 Proteasome inhibitors have a 20 year history in cancer therapy. The first proteasome inhibitor, bortezomib (Velcade, PS-341), a break-through multiple myeloma treatment, moved rapidly through development from bench in 1994 to first approval in 2003. Bortezomib is a reversible boronic acid inhibitor of the chymotrypsin-like activity of the proteasome ...
Teicher, Beverly A. +1 more
openaire +2 more sources
Inhibitory Effect of b-AP15 on the 20S Proteasome
Biomolecules, 2014 The 26S proteasome is a cellular proteolytic complex containing 19S regulatory particles and the 20S core proteasome. It was reported that the small molecule b-AP15 targets the proteasome by inhibiting deubiquitination of the 19S regulatory particles of
Li Huang, Katherine Jung, Chin Ho Chen
doaj +1 more source
The Proteasome Activator PA200/PSME4: An Emerging New Player in Health and Disease
Biomolecules, 2022 Proteasomes comprise a family of proteasomal complexes essential for maintaining protein homeostasis. Accordingly, proteasomes represent promising therapeutic targets in multiple human diseases.
Ayse Seda Yazgili +2 more
doaj +1 more source
Aptamer-Hytac Chimeras for Targeted Degradation of SARS-CoV-2 Spike-1
CellsThe development of novel tools to tackle viral processes has become a central focus in global health, during the COVID-19 pandemic. The spike protein is currently one of the main SARS-CoV-2 targets, owing to its key roles in infectivity and virion ...
Carme Fàbrega +7 more
doaj +1 more source